Enzo Biochem gets patent for producing therapeutic proteins

By Ted A. Knutson

Washington, Jan. 19 - Enzo Biochem, Inc. announced Thursday it has been issued a patent covering processes for producing large quantities of therapeutic proteins or RNAs within living target cells.

The unusual property of this invention is that it relies upon signals and regulatory elements that do not otherwise exist within the cell. This may allow for a large yield of the specific molecule desired, either the protein or the nucleic acid. By not bringing recognizable signaling moieties into the cell, it could add an element of efficiency and safety to the process.

The patent, U.S. patent number 6,986,985 titled "Process for Producing Multiple Nucleic Acid Copies In Vivo using a Protein Nucleic Acid Construct," was issued on Tuesday.

An important application of this technology may be to deliver therapeutic proteins to particular target cells in animals and humans, the company said. It may also facilitate delivery of regulatory RNA molecules, including antisense RNA molecules for the management of medically important diseases.

As such it could represent a potentially safer and a more efficient strategy for gene expression and protein production in mammals, including humans, the company said in a press release.

Farmingdale, N.Y.-based Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.